前立腺がん治療薬の世界市場:疫学予測

◆英語タイトル:Prostate cancer - Epidemiology Forecast to 2030
◆商品コード:DELV20JU217
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年5月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(217名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Prostate cancer – Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Prostate cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017-2030

Prostate cancer Understanding
The DelveInsight Prostate cancer epidemiology report gives a thorough understanding of the Prostate cancer by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Prostate cancer in the US, Europe, and Japan. The report covers the detailed information of the Prostate cancer epidemiology scenario in seven major countries (US, EU5, and Japan).

Prostate cancer Epidemiology Perspective by DelveInsight
The Prostate cancer epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Prostate cancer epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Prostate cancer epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Prostate cancer Detailed Epidemiology Segmentation
The Prostate cancer epidemiology covered in the report provides historical as well as forecasted Prostate cancer epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Prostate cancer report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report
The Prostate cancer report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
The Prostate cancer Epidemiology Report and Model provide an overview of the risk factors and global trends of Prostate cancer in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight about the historical and forecasted patient pool of Prostate cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Prostate cancer
The report provides the segmentation of the Prostate cancer epidemiology

Report Highlights
11-Year Forecast of Prostate cancer epidemiology
7MM Coverage
Total Cases of Prostate cancer
Total Cases of Prostate cancer according to segmentation
Diagnosed cases of Prostate cancer

KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Prostate cancer?
What are the key findings pertaining to the Prostate cancer epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
What would be the total number of patients of Prostate cancer across the 7MM during the forecast period (2017-2030)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
What is the disease risk, burden and unmet needs of the Prostate cancer?
What are the currently available treatments of Prostate cancer?

Reasons to buy
The Prostate cancer Epidemiology report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the global Prostate cancer market
Quantify patient populations in the global Prostate cancer market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Prostate cancer therapeutics in each of the markets covered
Understand the magnitude of Prostate cancer population by its epidemiology
The Prostate cancer Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

Prostate cancer- Market Insight, Epidemiology and Market Forecast -2030

【レポートの目次】

1. Key Insights

2. Executive Summary of Prostate cancer

3. Prostate cancer: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Prostate cancer Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Prostate cancer Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Prostate cancer Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Prostate cancer Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Prostate cancer Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Prostate cancer Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Prostate cancer Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Prostate cancer Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Prostate cancer Treatment and Management

6.2. Prostate cancer Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1 Prostate cancer Epidemiology in 7MM (2017-2030)

Table 2 Prostate cancer Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Prostate cancer Epidemiology in the United States (2017-2030)

Table 4 Prostate cancer Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Prostate cancer Epidemiology in Germany (2017-2030)

Table 6 Prostate cancer Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Prostate cancer Epidemiology in France (2017-2030)

Table 8 Prostate cancer Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Prostate cancer Epidemiology in Italy (2017-2030)

Table 10 Prostate cancer Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Prostate cancer Epidemiology in Spain (2017-2030)

Table 12 Prostate cancer Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Prostate cancer Epidemiology in the United Kingdom (2017-2030)

Table 14 Prostate cancer Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Prostate cancer Epidemiology in Japan (2017-2030)

Table 16 Prostate cancer Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Prostate cancer Epidemiology in 7MM (2017-2030)

Figure 2 Prostate cancer Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Prostate cancer Epidemiology in the United States (2017-2030)

Figure 4 Prostate cancer Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Prostate cancer Epidemiology in Germany (2017-2030)

Figure 6 Prostate cancer Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Prostate cancer Epidemiology in France (2017-2030)

Figure 8 Prostate cancer Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Prostate cancer Epidemiology in Italy (2017-2030)

Figure 10 Prostate cancer Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Prostate cancer Epidemiology in Spain (2017-2030)

Figure 12 Prostate cancer Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Prostate cancer Epidemiology in the United Kingdom (2017-2030)

Figure 14 Prostate cancer Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Prostate cancer Epidemiology in Japan (2017-2030)

Figure 16 Prostate cancer Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[前立腺がん治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆